ECOG performance status

Known as: ECOG Score, ECOG1-Performance Status, ECOG101 
A performance status scale designed to assess disease progression and its affect on the daily living abilities of the patient.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
OBJECTIVES Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been limited by the lack of a definitive… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
IMPORTANCE To integrate the patient perspective into adverse event reporting, the National Cancer Institute developed a patient… (More)
Is this relevant?
2015
2015
This phase 3 trial (Eastern Cooperative Oncology Group [ECOG] E1A06) compared melphalan, prednisone, and thalidomide (MPT-T) with… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
AIM The aim of our study was to assess whether the Karnofsky Performance Status (KPS), the Eastern Cooperative Oncology Group… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Plasma proteins [vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), carbonic anhydrase IX… (More)
  • figure 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE A phase III, randomized study was carried out to establish the most effective and safest treatment to improve the primary… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE/BACKGROUND The GONO-FOLFOXIRI regimen improved the rate of R0 secondary resection of metastases in initially… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND We demonstrated that circulating tumor cell (CTC) number at baseline and follow-up is an independent prognostic factor… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2007
2007
OBJECTIVES We tested and compared the improvement in prognostic ability related to the consideration of either ECOG performance… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND To the authors' knowledge, few data currently are available regarding the tolerance to chemotherapy in older cancer… (More)
Is this relevant?